

眼科学教室 2021, 2022 年度論文リスト

1. Inoue M, Koto T, Hirakata A: Flow dynamics of beveled-tip and flat-tip vitreous cutters. *Retina*. 41:445-453. 2021.
2. Inoue M, Aicher NT<sup>1</sup>, Itoh Y, Bissen-Miyajima H<sup>2</sup>, Hirakata A (<sup>1</sup>PMU-Paracelsus Medical Univ, <sup>2</sup>Tokyo Dental College Suidobashi Hospital): Quality of view through extended depth of focus intraocular lens in a model eye. *Jpn J Ophthalmol*. 65(4):569-580,2021.
3. Inoue M, Koto T, Hirakata A: Intraoperative optical coherence tomography-assisted displacement of prepapillary membrane in eyes with optic disc pit maculopathy. *Graefes Arch Clin Exp Ophthalmol*. 259(7):1703-1710.2021.
4. Keino H, Watanabe T, Nakayama M, Komagata Y<sup>1</sup>, Fukuoka K<sup>1</sup>, Okada AA(<sup>1</sup>Department of Rheumatology and Nephrology): Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet's disease. *Br J Ophthalmol*. 105(11):1525-1533. 2021.
5. Agrawal R, Testi I, Bodaghi B, Barisani-Asenbauer T, McCluskey P, Agarwal A, Kempen JH, Gupta A, Smith JR de Smet MD, Yuen YS, Mahajan S, Kon OM, Nguyen QD, Pavesio C, Gupta V; Collaborative Ocular Tuberculosis Study Consensus Group (including Okada AA). Collaborative Ocular Tuberculosis Study consensus guidelines on the management of tubercular uveitis – Report 2: Guidelines for initiating antitubercular therapy in anterior uveitis, intermediate uveitis, panuveitis, and retinal vasculitis. *Ophthalmology*. 128:277-287. 2021.
6. Murata T<sup>1</sup>, Kondo M<sup>2</sup>, Inoue M, Nakao S<sup>3</sup>, Osaka R<sup>4</sup>, Shiragami C<sup>4</sup>, Sogawa K<sup>5</sup>, Mochizuki A<sup>6</sup>, Shiraga R<sup>6</sup>, Ohashi Y<sup>6</sup>, Kaneko T<sup>6</sup>, Chandrasekhar C<sup>7</sup>, Tsujikawa A<sup>8</sup>, Kamei M<sup>9</sup> (<sup>1</sup>Shinshu University School of Medicine, <sup>2</sup>Mie University Graduate School of Medicine, <sup>3</sup>Kyushu University, <sup>4</sup>Kagawa University Faculty of Medicine, <sup>5</sup>Asahikawa Medical University, <sup>6</sup>Novartis Pharma K.K., <sup>7</sup>Novartis Healthcare Pvt. Ltd., <sup>8</sup>Kyoto University Graduate School of Medicine, <sup>9</sup>Aichi Medical University): The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naive patients. *Sci Rep*. 11(1):551. 2021.
7. Mitchell P, Rodriguez FJ, Jousseaume AM, Koh A, Eter N, Wong DT, Korobelnik JF, Okada AA. Management of retinal pigment epithelium tear during anti-vascular endothelial growth factor therapy. *Retina*. 41:671-678. 2021.
8. Baba T<sup>1</sup>, Kawasaki R<sup>2</sup>, Yamakiri K<sup>3</sup>, Koto T, Nishitsuka K<sup>4</sup>, Yamamoto S<sup>1</sup>, Sakamoto T<sup>3</sup>(<sup>1</sup>Chiba Univ, <sup>2</sup>Osaka Univ, <sup>3</sup>Kagoshima Univ, <sup>4</sup>Yamagata Univ); Japan-Retinal Detachment Registry Group : Visual outcomes after surgery for primary rhegmatogenous retinal detachment in era of microincision vitrectomy: Japan-Retinal Detachment Registry

- Report IV. *Br J Ophthalmol*. 105(2): 227-232. 2021.
9. Korobelnik JF, Loewenstein A, Eldem B, Jousseaume AM, Koh A, Lambrou GN, Lanzetta P, Li X, Lovestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodriguez FJ, Wong DT, Wu L. Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. *Graefes Arch Clin Exp Ophthalmol*. 259:657-574. 2021.
  10. Takeuchi J<sup>1</sup>, Kataoka K, Shimizu H<sup>1</sup>, Tomita R<sup>1</sup>, Kominami T<sup>1</sup>, Ushida H<sup>1</sup>, Kaneko H<sup>1</sup>, Ito Y<sup>1</sup>, Terasaki H<sup>1</sup> (<sup>1</sup>Nagoya Univ) : Intraoperative and postoperative monitoring of autologous neurosensory retinal flap transplantation for a refractory macular hole associated with high myopia. *Retina*. 41(5):921-930. 2021.
  11. Agrawal R, Testi I, Lee CS, Tsui E, Blazes M, Thorne JE, Okada AA, Smith JR, McCluskey PJ, Kempen JH, Tappeiner C, Agarwal M, Bodaghi B, Nguyen QD, Gupta V, De Smet MD, Zierhut M, Pavesio C: COVID-19 IMT Study Group. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic. *Br J Ophthalmol*. 105:639-647. 2021.
  12. Maruko I, Okada AA, Iida T, Hasegawa T, Izumi T, Kawai M, Maruko R, Nakayama M, Yamamoto A, Koizumi H, Tamashiro T, Terao N, Wakugawa S, Mori R, Onoe H, Tanaka K, Wakatsuki Y, Itagaki K, Kasai A, Ogasawara M, Sekiryu T, Shintake H, Sugano Y: Japan AMD Research Consortium: Brodalumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: A short-term multicenter study. *Graefes Arch Clin Exp Ophthalmol*. 259:2857-2859. 2021.
  13. Yaginuma S, Konno K, Shigeyasu C, Yamada M: Tear protein analysis in patients with primary acquired nasolacrimal duct obstruction treated with lacrimal passage intubation. *Jpn J Ophthalmol*. 65:409-415.2021.
  14. Hirakata T<sup>1,5</sup>, Fujinami K<sup>2,5,6</sup>, Saito W<sup>3,7</sup>, Kanda A<sup>3</sup>, Hirakata A, Ishida S<sup>3</sup>, Murakami A<sup>1</sup>, Tsunoda K<sup>5</sup>, Miyake Y<sup>4</sup> (<sup>1</sup>Juntendo Univ, <sup>2</sup>Keio Univ, <sup>3</sup>Hokkaido Univ, <sup>4</sup>Kobe Eye Center, <sup>5</sup>National Hosp Org Tokyo Med Center, <sup>6</sup>UCL Ins of Ophthalmol, <sup>7</sup>Kaimeido Eye and Dental Clin): Acute unilateral inner retinal dysfunction with photophobia: importance of electrodiagnosis. *Jpn J Ophthalmol*. 65(1):42-53. 2021.
  15. Ishida T, Fukumoto R, Wakabayashi Y<sup>1</sup>, Itoh Y, Inoue M, Hirakata A(<sup>1</sup>Tokyo Med Univ): Case of peripheral fibrovascular proliferative retinopathy associated with morning glory disc anomaly. *Am J Ophthalmol Case Rep*. 22:101029. eCollection. 2021.
  16. Kato Y, Inoue M, Hirakata A: Effect of foveal vitreous cortex removal to prevent epiretinal membrane after vitrectomy and scleral buckling. *Ophthalmol Retina*. 5(5):420-428. 2021.
  17. Koto T, Kawasaki R<sup>1</sup>, Yamakiri K<sup>2</sup>, Baba T<sup>3</sup>, Nishitsuka K<sup>4</sup>, Hirakata A, Sakamoto T<sup>2</sup>; Japan-Retinal Detachment Registry Group (<sup>1</sup>Osaka Univ, <sup>2</sup>Kagoshima Univ, <sup>3</sup>Chiba Univ,

- <sup>4</sup>Yamagata Univ): Six months primary success rate for retinal detachment between vitrectomy and scleral buckling. *Retina*. 41(6):1164-1173. 2021.
18. Kita Y, Holló G<sup>1</sup>, Narita F, Kita R, Hirakata A (<sup>1</sup>Semmelweis Univ) : Myopic Peripapillary Pits with Spatially Corresponding Localized Visual Field Defects: A Progressive Japanese and a Cross-Sectional European Case. *Case Rep Ophthalmol*. 12(2):350-355. 2021.
  19. Ito Y<sup>1</sup>, Ito M<sup>1</sup>, Iwase T<sup>1</sup>, Kataoka K<sup>1</sup>, Yamada K<sup>1</sup>, Yasuda S<sup>1</sup>, Ito H<sup>1</sup>, Takeuchi J<sup>1</sup>, Nakano Y<sup>1</sup>, Fujita A<sup>1</sup>, Horiguchi E<sup>1</sup>, Taki Y<sup>1</sup>, Yatsuya H<sup>1</sup>, Terasaki H<sup>1</sup> (<sup>1</sup>Nagoya Univ): Prevalence of and factors associated with dilated choroidal vessels beneath the retinal pigment epithelium among the Japanese. *Sci Rep*. 11(1):11278. 2021.
  20. Kaneko H<sup>1</sup>, Hirata N<sup>1</sup>, Shimizu H<sup>1</sup>, Kataoka K, Nonobe N<sup>1</sup>, Mokuno K<sup>1</sup>, Terasaki H<sup>1</sup> (<sup>1</sup>Nagoya Univ): Effect of internal limiting membrane peeling on visual field sensitivity in eyes with epiretinal membrane accompanied by glaucoma with hemifield defect and myopia. *Jpn J Ophthalmol*. 65(3):380-387. 2021.
  21. Kataoka K, Horiguchi E<sup>1</sup>, Kawano K<sup>1</sup>, Ushida H<sup>1</sup>, Nakano Y<sup>1</sup>, Ito Y<sup>1</sup>, Terasaki H<sup>1</sup> (<sup>1</sup>Nagoya Univ) : Three cases of brolocizumab-associated retinal vasculitis treated with systemic and local steroid therapy. *Jpn J Ophthalmol*. 65(2):199-207. 2021.
  22. Tsunekawa Y<sup>1</sup>, Kataoka K, Asai K<sup>1</sup>, Ito Y<sup>1</sup>, Terasaki H<sup>1</sup> (<sup>1</sup>Nagoya University Graduate School of Medicine) : Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration. *Jpn J Ophthalmol*. 65(1):69-76. 2021.
  23. Sonoda K, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H, JOIS (Japanese Ocular Inflammation Society) Uveitis Survey Working Group : Epidemiology of uveitis in Japan ; a 2016 retrospective nationwide survey. *Jpn J Ophthalmol* 65(2):184-190. 2021.
  24. Takashi N<sup>1</sup>, Nakamura A<sup>1</sup>, Kataoka K, Usui Y<sup>1</sup>, Ito Y<sup>1</sup>, Kaneko H<sup>1</sup> (<sup>1</sup>Nagoya Univ) : Optical coherence tomography angiography for the diagnosis of granulomatosis with polyangiitis with serous retinal detachment ; A case report. *Medicine (Baltimore)*. 100(7):e24789. 2021.
  25. Fujita A<sup>1</sup>, Kataoka K, Takeuchi J<sup>1</sup>, Nakano Y<sup>1</sup>, Horiguchi E<sup>1</sup>, Kaneko H<sup>1</sup>, Ito Y<sup>1</sup>, Terasaki H<sup>1</sup>(<sup>1</sup>Nagoya Univ): Reply. *Retina*. 41(9):e54. 2021.
  26. Saito-Uchida S, Inoue M, Koto T, Kato Y, Hirakata A: Vitrectomy combined with subretinal injection of tissue plasminogen activator for successful treatment of massive subretinal hemorrhage. *Eur J Ophthalmol*. 31(5):2588-2595. 2021.
  27. Tallouzi MO, Mathers JM, Moore DJ, Bucknall N, Calvert MJ, Murray PI, Denniston AK, COSUMO Working Group (including Okada AA): Development of a core outcome set for clinical

- trials in non-infectious posterior segment-involving uveitis. *Ophthalmology*. 128(8):1209-1221. 2021.
28. Umazume A<sup>1</sup>, Ohguro N<sup>2</sup>, Okada AA, Namba K<sup>3</sup>, Sonoda KH<sup>4</sup>, Tsuruga H<sup>5</sup>, Morita K<sup>5</sup>, Goto H<sup>1</sup>(<sup>1</sup>Tokyo Medical University, <sup>2</sup>Osaka Hospita, <sup>3</sup>Hokkaido Univ, <sup>4</sup>Kyushu Univ, <sup>5</sup> AbbVie GK) : Prevalence and incidence rates and treatment patterns of non-infectious uveitis in Japan: real-world data using a claims database. *Jpn J Ophthalmol*. 65(5):657-665. 2021.
  29. Sadamatsu Y<sup>1</sup>, Ono K<sup>1</sup>, Hiratsuka Y<sup>1</sup>, Takesue A<sup>1</sup>, Tano T<sup>1</sup>, Yamada M, Otani K<sup>2</sup>, Sekiguchi M<sup>2</sup>, Konno S<sup>2</sup>, Kikuchi S<sup>2</sup>, Fukuhara S<sup>3</sup>, Murakami A<sup>1</sup> (<sup>1</sup>Juntendo Univ, <sup>2</sup>Fukushima Univ, <sup>3</sup>Kyoto Univ): Prevalence and factors associated with uncorrected presbyopia in a rural population of Japan: the Locomotive syndrome and health outcome in Aizu Cohort Study. *Jpn J Ophthalmol*. 65(5):724-730. 2021.
  30. Mitsukawa T, Suzuki Y, Momota Y, Suzuki S, Yamada M: Effects of 0.01% atropine instillation assessed using swept-source anterior segment optical coherence tomography. *J Clin Med*. 10(19):4384. 2021.
  31. Fukumoto R, Inoue M, Ishida T, Koto T, Hirakata A: Adjustment of intraocular lens tilt during intrascleral fixation assisted by intraoperative OCT. *J Cataract Refract surg*. 47(10):1308-1313. 2021.
  32. Ohji M<sup>1</sup>, Okada AA, Sasaki K<sup>2</sup>, Moon SC<sup>2</sup>, Machewitz T<sup>3</sup>, Takahashi K<sup>4</sup>, ALTAIR Investigators(<sup>1</sup>Shiga Univ, <sup>2</sup>Bayer Yakuhin Ltd.,<sup>3</sup>Bayer AG, <sup>4</sup>Kansai Med Univ): Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. *Graefes Arch Clin Exp Ophthalmol*. 259(12):3637-3647. 2021.
  33. Sano M, Hirakata A, Kita Y, Itoh Y, Koto T, Inoue M: Risk factors for failure of resolving optic disc pit maculopathy after primary vitrectomy without laser photocoagulation. *Jpn J Ophthalmol*. 65(6):786-796. 2021.
  34. Takase H, Acharya NR, Babu K, Bodaghi B, Khairallah M, McCluskey PJ, Tesavibul N, Thorne JE, Tugal-Tutkun I, Yamamoto JH, Rao NA, 7th IWOS Study Group (including Okada AA), Smith JR, Mochizuki M: Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis. *Br J Ophthalmol*. 105(11):1515-1519. 2021.
  35. Sato Y<sup>1</sup>, Keino H, Nakayama M, Kano M, Okada AA(<sup>1</sup> Division of Radioisotope Research): Effect of In Vivo Expansion of Regulatory T Cells with IL-2/anti-IL-2 Antibody Complex Plus Rapamycin on Experimental Autoimmune Uveoretinitis. *Ocul Immunol Inflamm*. 29: 1520-1529. 2021.

36. Takamura Y<sup>1</sup>, Kida T<sup>2</sup>, Noma H<sup>3</sup>, Inoue M, Yoshida S<sup>4</sup>, Nagaoka T<sup>5</sup>, Noda K<sup>6</sup>, Yamada Y<sup>1</sup>, Morioka M<sup>1</sup>, Gozawa M<sup>1</sup>, Matsumura T<sup>1</sup> Inatani M<sup>1</sup>(<sup>1</sup> Univ of Fukui, <sup>2</sup> Osaka Med and Pharm Univ, <sup>3</sup> Tokyo Med Univ, <sup>4</sup> Kurume Univ, <sup>5</sup> Nihon Univ Itabashi Hosp, <sup>6</sup> Hokkaido Univ): The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen. *J Clin Med*. 10(24):5738. 2021.
37. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for birdshot chorioretinitis. *Am J Ophthalmol*. 228:65-71. 2021.
38. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for multiple sclerosis-associated intermediate uveitis. *Am J Ophthalmol*. 228:72-79. 2021.
39. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for Behçet disease uveitis. *Am J Ophthalmol*. 228:80-88. 2021.
40. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for cytomegalovirus anterior uveitis. *Am J Ophthalmol*. 228:89-95. 2021.
41. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Development of classification criteria for the uveitides. *Am J Ophthalmol*. 228:96-116. 2021.
42. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for spondyloarthritis/HLA-B27-associated anterior uveitis. *Am J Ophthalmol*. 228:117-125. 2021.
43. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for serpiginous choroiditis. *Am J Ophthalmol*. 228:126-133. 2021.
44. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for toxoplasmic retinitis. *Am J Ophthalmol*. 228:134-141. 2021.
45. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for tubercular uveitis. *Am J Ophthalmol*. 228:142-151. 2021.
46. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for multifocal choroiditis with panuveitis. *Am J Ophthalmol*. 228:152-158. 2021.
47. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for intermediate uveitis, non-pars planitis type. *Am J Ophthalmol*. 228:159-164. 2021.
48. The Standardization of Uveitis Nomenclature Working Group (including Okada AA): Classification criteria for varicella zoster virus anterior uveitis. *Am J Ophthalmol*. 228:165-173. 2021.

49. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for acute posterior multifocal placoid pigment epitheliopathy. *Am J Ophthalmol.* 228:174-181. 2021.
50. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for syphilitic uveitis. *Am J Ophthalmol.* 228:182-191. 2021.
51. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for juvenile idiopathic arthritis-associated chronic anterior uveitis. *Am J Ophthalmol.* 228:192-197. 2021.
52. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for multiple evanescent white dot syndrome. *Am J Ophthalmol.* 228:198-204. 2021.
53. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for Vogt-Koyanagi-Harada disease. *Am J Ophthalmol.* 228:205-211. 2021.
54. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for sympathetic ophthalmia. *Am J Ophthalmol.* 228:212-219. 2021.
55. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for sarcoidosis-associated uveitis. *Am J Ophthalmol.* 228:220-230. 2021.
56. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for herpes simplex virus anterior uveitis. *Am J Ophthalmol.* 228:231-236. 2021.
57. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for acute retinal necrosis syndrome. *Am J Ophthalmol.* 228:237-244. 2021.
58. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for cytomegalovirus retinitis. *Am J Ophthalmol.* 228:245-254. 2021.
59. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for tubulointerstitial nephritis with uveitis syndrome. *Am J Ophthalmol.* 228:255-261. 2021.
60. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for Fuchs uveitis syndrome. *Am J Ophthalmol.* 228:262-267. 2021.
61. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for pars planitis. *Am J Ophthalmol.* 228:268-274. 2021.
62. The Standardization of Uveitis Nomenclature Working Group (including Okada AA):  
Classification criteria for punctate inner choroiditis. *Am J Ophthalmol.* 228:275-280. 2021.

63. Kawano S, Imai T, Sakamoto T; Japan-Retinal Detachment Registry Group(Hirakata A): Scleral buckling versus pars plana vitrectomy in simple phakic macula-on retinal detachment: a propensity score-matched, registry-based study. *Br J Ophthalmol*. 2021. [Online ahead of print]
64. Yang F<sup>1</sup>, Hayashi I<sup>1</sup>, Sato S<sup>1</sup>, Saijo-Ban Y<sup>1</sup>, Yamane M<sup>1</sup>, Fukui M<sup>1</sup>, Shimizu E<sup>1</sup>, He J<sup>2</sup>, Shibata S<sup>1</sup>, Mukai S<sup>3</sup>, Asai K<sup>1</sup>, Ogawa M<sup>1</sup>, Lan Y<sup>4</sup>, Zeng Q<sup>5</sup>, Hirakata A, Tsubota K<sup>1</sup>, Ogawa Y<sup>1</sup>(<sup>1</sup>Keio Univ, <sup>2</sup>The Second Affiliated Hosp of Zhejiang Univ, <sup>3</sup> Harvard Univ, <sup>4</sup>Sun Yat-sen Univ, <sup>5</sup>Aier Eye Hosp of Wuhan Univ): Eyelid blood vessel and meibomian gland changes in a sclerodermatous chronic GVHD mouse model. *Ocul Surf*. S1542-0124(21)00123-3. 2021.[Online ahead of print]
65. Funahashi S<sup>1</sup>, Ito Y<sup>1</sup>, Kataoka K, Takeuchi J<sup>1</sup>, Nakano Y<sup>1</sup>, Fujita A<sup>1</sup>, Horiguchi E<sup>1</sup>, Taki Y<sup>1</sup>, Terasaki H<sup>1</sup> (<sup>1</sup>Nagoya Univ) : Spontaneous closure of macular hole after vitrectomy for myopic retinoschisis with foveal detachment. *Retin Cases Brief Rep*. 2021. [Online ahead of print]
66. Suwa S<sup>1</sup>, Tomita R<sup>1</sup>, Kataoka K<sup>1</sup>, Ueno S<sup>1</sup> (<sup>1</sup>Nagoya Univ): Development of Vogt-Koyanagi-Harada Disease-like uveitis during treatment by anti-programmed death ligand-1 antibody for non-small cell lung cancer: A Case Report. *Ocul Immunol Inflamm*. 2021. [Online ahead of print]
67. Ito H<sup>1</sup>, Ito Y<sup>1</sup>, Kataoka K<sup>1</sup>, Ueno S<sup>1</sup>, Takeuchi J<sup>1</sup>, Nakano Y<sup>1</sup>, Fujita A<sup>1</sup>, Horiguchi E<sup>1</sup>, Kaneko H<sup>1</sup>, Iwase T<sup>1</sup>, Terasaki H<sup>1</sup> (<sup>1</sup>Nagoya Univ): Erratum to association between retinal layer thickness and perfusion status in extramacular areas in diabetic retinopathy. *Am J Ophthalmol*. 2021. [Online ahead of print]
68. Fujita A<sup>1</sup>, Kataoka K, Takeuchi J<sup>1</sup>, Nakano Y<sup>1</sup>, Horiguchi E<sup>1</sup>, Kaneko H<sup>1</sup>, Ito Y<sup>1</sup>, Terasaki H<sup>1</sup> (<sup>1</sup>Nagoya Univ) : Author response to diagnostic characteristics of b-scan swept-source optical coherence tomography for patients with polypoidal choroidal vasculopathy. *Retina*. 2021. [Online ahead of print]
69. Tamura H<sup>1</sup>, Akune Y<sup>2</sup>, Hiratsuka Y<sup>3</sup>, Kawasaki R<sup>4</sup>, Kido A<sup>1</sup>, Miyake M<sup>1</sup>, Goto R<sup>2</sup>, Yamada M (<sup>1</sup>Kyoto Univ, <sup>2</sup>Keio Univ, <sup>3</sup>Juntendo Univ, <sup>4</sup> Osaka Univ): Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI. *Jpn J Ophthalmol*. 66(1):19-32. 2022.
70. Shigeyasu C, Yamada M, Fukuda M<sup>1</sup>, Koh S<sup>2</sup>, Suzuki T<sup>3</sup>, Toshida H<sup>4</sup>, Oie Y<sup>2</sup>, Nejima R<sup>5</sup>, Eguchi H<sup>1</sup>, Kawasaki R<sup>2</sup>, Nishida K<sup>2</sup>, Research Group of Severe Contact Lens-associated Ocular Complications (<sup>1</sup>Kinki Univ, <sup>2</sup>Osaka Univ, <sup>3</sup>Toho Univ, <sup>4</sup>Juntendo Univ, <sup>5</sup>Miyata Ganka Hosp): Severe ocular complications associated with wearing of contact lens in

- Japan. *Eye Contact Lens*. 48(2):63-68. 2022.
71. Inoue M, Koto T, Hirakata A: Comparisons of flow dynamics of dual-blade to single-blade beveled-tip vitreous cutters. *Ophthalmic Res*. 65(2):216-228. 2022.
  72. Okano K, Ishida T, Inoue M, Hirakata A: Retinal detachment and retinoschisis associated with optic disc pit in peripapillary staphyloma. *Am J Ophthalmol Case Rep*. 26:101468. eCollection. 2022.
  73. Ando Y, Keino H, Inoue M, Hirota K, Takahashi H, Sano K, Koto T, Sato T, Takeuchi M, Hirakata A: Circulating vitreous microRNA as possible biomarker in high myopic eyes with macular hole. *Int J Mol Sci*. 23(7):3647. 2022.
  74. Okada AA, Palestine A, Kramer M, Jabs DA, Standardization of Uveitis Nomenclature (SUN) Working Group: Reply to Comment on "Classification criteria for Behcet disease uveitis." *Am J Ophthalmol*. 235:339-340. 2022.
  75. Hiratsuka Y<sup>1</sup>, Ono K<sup>1</sup>, Takesue A<sup>1</sup>, Sadamatsu Y<sup>1</sup>, Yamada M, Otani K, Konno S<sup>2</sup>, Fukuhara S<sup>3</sup>, Murakami A<sup>1</sup> (<sup>1</sup>Juntendo Univ, <sup>2</sup>Fukushima Univ, <sup>3</sup>Kyoto Univ): The prevalence of uncorrected refractive error in Japan: the Locomotive Syndrome and Health Outcome in Aizu Cohort Study. *Jpn J Ophthalmol*. 66(2):199-204. 2022.
  76. Yamakiri K<sup>1</sup>, Sakamoto T<sup>1</sup>, Koriyama C<sup>2</sup>, Kawasaki R<sup>2</sup>, Baba T<sup>3</sup>, Nishitsuka K<sup>4</sup>, Koto T, Terasaki H<sup>1</sup>; Japan Retinal Detachment Registry (<sup>1</sup>Kagoshima Univ, <sup>2</sup>Osaka Univ, <sup>3</sup>Chiba Univ, <sup>4</sup>Yamagata Univ): Effect of surgeon-related factors on outcome of retinal detachment surgery: analyses of data in Japan-retinal detachment registry. *Sci Rep*. 12(1):4213. 2022.
  77. Tamashiro T, Tanaka K, Itagaki K, Nakayama M, Maruko I, Wakugawa S, Terao N, Onoe H, Wakatsuki Y, Ogasawara M, Sugano Y, Yamamoto A, Kataoka K, Izumi T, Kawai M, Mori R, Sekiryu T, Okada AA, Iida T, Koizumi H; Japan AMD Research Consortium (JARC): Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study. *Graefes Arch Clin Exp Ophthalmol*. 260:1857-1865:2022.
  78. Takase H<sup>1</sup>, Goto H<sup>2</sup>, Namba K<sup>3</sup>, Mizuki N<sup>4</sup>, Okada AA, Ohguro N<sup>5</sup>, Sonoda KH<sup>6</sup>, Tomita M<sup>1</sup>, Keino H, Kezuka T<sup>2</sup>, Kubono R<sup>1</sup>, Mizuuchi K<sup>3</sup>, Shibuya E<sup>4</sup>, Takahashi H<sup>1</sup>, Yanai R<sup>7</sup>, Mochizuki M<sup>1</sup>, Japan ARN Study Group (<sup>1</sup>National Defense Medical Col, <sup>2</sup>Tokyo Medical Univ, <sup>3</sup>Hokkaido Univ, <sup>4</sup>Yokohama City Univ, <sup>5</sup>Japan Community Health Care Org Osaka Hosp, <sup>6</sup>Kyushu Univ, <sup>7</sup>Yamaguchi Univ): Clinical characteristics, management, and factors associated with poor visual prognosis of acute retinal necrosis. *Ocul Immunol Inflamm*. 30(1):48-53. 2022.
  79. Ota H<sup>1</sup>, Takeuchi J<sup>1</sup>, Nakano Y<sup>1</sup>, Horiguchi E<sup>1</sup>, Taki Y<sup>1</sup>, Ito Y<sup>1</sup>, Terasaki H<sup>1</sup>, Nishiguchi KM<sup>1</sup>,



Kataoka K (<sup>1</sup>Nagoya Univ): Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration. *Jpn J Ophthalmol.* 66:278-284. 2022.

80. Yogeswaran K<sup>1</sup>, Furtado JM<sup>2</sup>, Bodaghi B<sup>3</sup>, Matthews JM, International Ocular Toxoplasmosis Study Group (including Okada AA), Smith JR<sup>1</sup> (<sup>1</sup>Flinders University, <sup>2</sup>University of São Paulo, <sup>3</sup>Hopital Pitie-Salpetriere): Current practice in the management of ocular toxoplasmosis. *Br J Ophthalmol.* 2022. [Online ahead of print]
81. Ohno-Matsui K<sup>1</sup>, Akiba M<sup>2</sup>, Ishibashi T<sup>3</sup>, Hirakata A(<sup>1</sup>Tokyo Med Den Univ, <sup>2</sup>Topcon Corp, <sup>3</sup>Kyushu Univ): Evaluation of morning glory syndrome by swept-source optical coherence tomography. *Retin Cases Brief Rep.* 2022. [Online ahead of print]
82. Nakayama M, Okada AA, Hayashi I, Ando Y, Watanabe T, Keino H: A COVID-19 risk reduction strategy for the treatment of acute Vogt-Koyanagi-Harada Disease utilizing the antiviral potential of cyclosporine. *Ocul Immunol Inflamm.* 2022. [Online ahead of print]